S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
China Threat Triggers Potential Mining Boom for Investors (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
China Threat Triggers Potential Mining Boom for Investors (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
China Threat Triggers Potential Mining Boom for Investors (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
China Threat Triggers Potential Mining Boom for Investors (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
China Threat Triggers Potential Mining Boom for Investors (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
NASDAQ:CMRX

Chimerix - CMRX Stock Forecast, Price & News

$2.22
-0.03 (-1.33%)
(As of 12/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.18
$2.32
50-Day Range
$1.67
$2.35
52-Week Range
$1.27
$7.42
Volume
974,371 shs
Average Volume
2.74 million shs
Market Capitalization
$195.46 million
P/E Ratio
1.27
Dividend Yield
N/A
Price Target
$8.50

Chimerix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
282.9% Upside
$8.50 Price Target
Short Interest
Healthy
4.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.49
Upright™ Environmental Score
News Sentiment
0.99mentions of Chimerix in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$37,200 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From $1.97 to ($0.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.88 out of 5 stars

Medical Sector

16th out of 1,033 stocks

Pharmaceutical Preparations Industry

5th out of 502 stocks

CMRX stock logo

About Chimerix (NASDAQ:CMRX) Stock

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Stock News Headlines

Hedge fund urges Durham drugmaker Chimerix to liquidate
Chimerix Responds to Rubric Capital Management
Buy 3 of the Best Stocks by Using Net Income Ratio
Chimerix (CMRX) Beats Q3 Earnings Estimates
See More Headlines
Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Company Calendar

Last Earnings
11/04/2021
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMRX
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.50
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+282.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-173,240,000.00
Pretax Margin
465.22%

Debt

Sales & Book Value

Annual Sales
$1.98 million
Book Value
$0.79 per share

Miscellaneous

Free Float
80,825,000
Market Cap
$195.46 million
Optionable
Optionable
Beta
1.14

Key Executives

  • Mr. Michael A. Sherman M.B.A. (Age 56)
    CEO, Pres & Director
    Comp: $987.2k
  • Mr. Michael T. Andriole M.B.A. (Age 49)
    Chief Bus. Officer, Sec. & CFO
    Comp: $616.9k
  • Dr. Allen S. Melemed M.B.A. (Age 58)
    M.D., Chief Medical Officer
    Comp: $622.17k
  • Mr. David Jakeman CPA (Age 44)
    Exec. Director of Fin. & Accounting and Principal Accounting Officer
  • Dr. Roy W. Ware
    Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier
    Chief Science Officer
  • Ms. Michelle LaSpaluto
    VP of Strategic Planning & Investor Relations
  • Dr. Michael A. Alrutz (Age 52)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Dr. Joshua E. Allen
    Chief Technology Officer of Imipridones













CMRX Stock - Frequently Asked Questions

Should I buy or sell Chimerix stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings
or view top-rated stocks.

What is Chimerix's stock price forecast for 2023?

3 brokers have issued twelve-month price targets for Chimerix's shares. Their CMRX share price forecasts range from $6.00 to $11.00. On average, they expect the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 282.9% from the stock's current price.
View analysts price targets for CMRX
or view top-rated stocks among Wall Street analysts.

How have CMRX shares performed in 2022?

Chimerix's stock was trading at $6.43 at the beginning of the year. Since then, CMRX shares have decreased by 65.5% and is now trading at $2.22.
View the best growth stocks for 2022 here
.

Are investors shorting Chimerix?

Chimerix saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 3,170,000 shares, a decline of 8.9% from the October 31st total of 3,480,000 shares. Based on an average trading volume of 1,750,000 shares, the short-interest ratio is currently 1.8 days. Approximately 4.3% of the company's shares are short sold.
View Chimerix's Short Interest
.

When is Chimerix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our CMRX earnings forecast
.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.21) EPS for the quarter, meeting analysts' consensus estimates of ($0.21). The biopharmaceutical company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.39 million. Chimerix had a trailing twelve-month return on equity of 147.04% and a net margin of 464.75%. During the same quarter in the prior year, the business earned ($0.18) earnings per share.

What other stocks do shareholders of Chimerix own?
What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Who are Chimerix's major shareholders?

Chimerix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rubric Capital Management LP (7.52%), BlackRock Inc. (6.55%), Vanguard Group Inc. (5.10%), State Street Corp (3.31%), Armistice Capital LLC (3.13%) and Monaco Asset Management SAM (2.41%). Insiders that own company stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends
.

How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $2.22.

How much money does Chimerix make?

Chimerix (NASDAQ:CMRX) has a market capitalization of $195.46 million and generates $1.98 million in revenue each year. The biopharmaceutical company earns $-173,240,000.00 in net income (profit) each year or $1.75 on an earnings per share basis.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146.

This page (NASDAQ:CMRX) was last updated on 12/6/2022 by MarketBeat.com Staff